CHRNA5 and nicotine: behind the scenes.

Before we load up a Story for our subscribers, the GenEd team reads a lot of literature. A LOT OF LITERATURE. We cull through the peer-reviewed article and reconstruct a historical narrative from the discovery of the variant to the latest interpretation of human phenotypes. At the very end we have two capsule synopses: one for scientists and one for beginners. Here's our "for scientists" summary for the rs16969968 SNP in CHRNA5: "CHRNA5, a well-studied gene in multiple human studies on the genetics of addiction, encodes the alpha 5 subunit of the nicotinic acetylcholine receptor. The rs16969968 SNP changes a phylogenetically conserved aspartate to an asparagine (D398N). The N398 protein has lower maximal responses to nAchR agonists and is strongly associated with increased risk of nicotine addiction. A mouse model of CHRNA5 knockout shows that the alpha5 subunit mediates transmission of aversive stimuli from the habenula to the VTA, decreasing dopamine release at the NAc. Carriers of the rs16969968 rare allele are predicted to have a blunted response to the aversive stimuli associated with drug intake, leading to increased consumption. Human fMRI studies show that the N398 allele is associated with reduced synchronization of a cortex-midbrain circuit involved in addiction behavior." Sounds a lot like most of the "reports" you've probably read for genetics results. Here's our "for beginners" summary for the same SNP in the same gene: "The scientific literature on the rare rs16969968 A allele is complex. In short, this genetic change seems to do two things. First, it lowers the response of the nicotine receptor to the brain’s own stimulating chemicals, lowering dopamine tone. And second, it seems to decrease a different function of the nicotine receptor, that of lowering dopamine when a noxious chemical is taken in. Together, the low basal tone that mediates for a person’s wanting to take something to feel better and the poor response to the noxious effect of certain chemicals creates a greater risk for addiction involving substances that others might find to be not a good drug (tobacco smoke)." Note that the "for beginners" summary has very few abbreviations and focuses closely on what a non-scientist human would care about. We'll make more posts in the future about the process of creating a GenEd Story. If you're interested in learning more, use the "Contact Us" link in the navbar above, or register and upload data to see your free MTHFR report.

ACE2 and Coronavirus Story is LIVE

Have you been digesting the news about Wuhan coronavirus? We've put together a great Story explaining a pretty cool part of coronavirus biology: ACE2. It turns out that SARS and 2019-nCoV both use the membrane protein ACE2 as their receptor for cell entry. In other words, ACE2 is the "hook" that these two coronaviruses use to latch onto their target cells in the lungs. Does ACE2 sound familiar? You're probably more familiar with its close homologue and homeostatic partner, ACE or ACE1. ACE is one of the master regulators of the renin-angiotensin system, a classic target of anti-hypertensive drugs. We're pretty excited about this Story. Join GenEd, upload your data, and expand your mind!

. . . Aaaand our email is back!

Thanks for being patient with us while we dealt with our site migration issue. If you were unable to contact us about something important the past few days, reach out to my now functioning email:

Email servers are out

If you've tried to contact us in the past few days, we're having issues with the site migration affecting our email server (yay technology). If you need immediate assistance, please contact Steve by voice or text at our customer service number: (985) 212-0062.

Your OPRM1 Story is now live!

Login and Click on the GenEd logo to the upper left to go to your GenEd home page. Once there, pay for a Member+ subscription (if you haven't already paid), and take a personalized tour through the biology of your endorphins and opioids! If you have any trouble, contact Steve at

1 2 3